IMRIS Inc. (IMRSQ) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
IMRIS Inc. (IMRSQ) trades at $0.00001 with AI Score 46/100 (Grade C). IMRIS Inc. is a Canadian healthcare company specializing in advanced image-guided therapy solutions, primarily through its VISIUS Surgical Theatre. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for IMRSQ: IMRSQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IMRSQ against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IMRSQ: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
IMRIS Inc. (IMRSQ) Healthcare & Pipeline Overview
IMRIS Inc., established in 2005, is a Canadian healthcare company specializing in advanced image-guided therapy solutions. Its flagship VISIUS Surgical Theatre integrates real-time MRI, CT, and fluoroscopy into operating rooms, enhancing precision for neurosurgical, spinal, and cardiovascular procedures. The company provides critical intraoperative visual data, positioning it as a niche leader in high-acuity medical device technology.
What Is the Investment Thesis for IMRSQ?
IMRIS Inc. operates in a specialized segment of the medical device market, focusing on intraoperative imaging solutions through its VISIUS Surgical Theatre. The company's unique value proposition lies in providing real-time MRI, CT, and fluoroscopy directly within surgical suites, which enhances precision and decision-making in complex neurosurgical, spinal, and cardiovascular procedures. This niche specialization caters to a critical demand for improved surgical outcomes and patient safety. However, the company's financial profile, marked by a -105.2% profit margin and a $0.00B market capitalization, indicates significant operational challenges. Its listing on the OTC Other tier further signals a heightened risk profile, potentially reflecting financial distress or regulatory non-compliance, necessitating rigorous due diligence. While the specialized product offers a potential competitive advantage, the company's ability to achieve operational viability and sustained profitability within the competitive medical technology landscape remains a key consideration for investors.
Based on FMP financials and quantitative analysis
IMRSQ Key Highlights
Market Capitalization: $0.00B, indicating a micro-cap or non-reporting entity status.
- Profit Margin: -105.2%, reflecting substantial net losses relative to revenue.
- Gross Margin: 34.4%, suggesting a moderate margin on product sales before operating expenses.
- Beta: 7.79, indicating extremely high volatility relative to the broader market.
- Dividend Yield: None, as the company does not currently distribute dividends to shareholders.
Who Are IMRSQ's Competitors?
IMRSQ is benchmarked below against 7 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACIXF Acarix AB (publ) | $0.03 | +0.00% | $31.5M | 52 |
| TRXDW TransEnterix, Inc. | $0.15 | -11.76% | $40.1M | 53 |
| EBRCZ EBR Systems, Inc. | $0.21 | -11.02% | $134M | 45 |
| SI SHOULDER INNOVATIONS, INC. | $23.26 | +10.08% | $482M | 30 |
| AVNBF Avon Technologies Plc | $22.49 | +0.00% | $662M | 38 |
| EBOSY EBOS Group Limited | $26.00 | +0.00% | $1.33B | 42 |
| BMXXY bioMérieux S.A. | $8.56 | +7.81% | $10.1B | 46 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IMRSQ's Key Strengths?
Specialized and integrated VISIUS Surgical Theatre offers real-time intraoperative imaging (MRI, CT, fluoroscopy).
- Enhances precision and decision-making in complex neurosurgical, spinal, cerebrovascular, and cardiovascular procedures.
- Established in 2005, indicating a history of operation in the medical device sector.
- Offers recurring revenue streams through service plans and accessories.
What Are IMRSQ's Weaknesses?
Significant negative profit margin (-105.2%) indicates substantial financial losses.
- Market capitalization of $0.00B suggests a very small or distressed financial standing.
- Trading on the OTC Other tier, implying heightened risk, potential financial distress, or regulatory non-compliance.
- High Beta of 7.79, indicating extreme stock price volatility.
What Could Drive IMRSQ Stock Higher?
Continued demand for advanced image-guided therapy solutions in neurosurgical and cardiovascular specialties.
- Revenue generation from comprehensive service plans and extended maintenance agreements on existing VISIUS Surgical Theatre installations.
- Development and distribution of essential accessories and disposables, contributing to recurring revenue streams.
- Potential for technological advancements or new product iterations that could enhance the VISIUS Surgical Theatre's capabilities and market appeal.
What Are the Key Risks for IMRSQ?
Financial-distress signal — its Altman Z-Score of -4.51 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Significant negative profit margin (-105.2%) indicating persistent operational losses and potential financial instability.
- Heightened risk profile associated with trading on the OTC Other tier, including potential financial distress or regulatory non-compliance.
- Intense competition within the medical device sector from larger, more established players with greater resources.
- Challenges in maintaining operational viability and achieving sustained profitability given the current financial metrics.
- Regulatory hurdles and compliance costs inherent in the medical device industry, potentially impacting market access or product development.
What Are the Growth Opportunities for IMRSQ?
- Expansion into New Therapeutic Areas: The core technology of the VISIUS Surgical Theatre, which provides real-time intraoperative imaging, holds potential for application beyond its current neurosurgical, spinal, cerebrovascular, and cardiovascular specialties. Expanding into areas such as oncology (e.g., image-guided tumor resections), orthopedic surgery, or pediatric surgery could significantly broaden the addressable market. The global market for image-guided surgery is projected to grow, and diversifying clinical applications could capture a larger share, with potential for new installations and recurring service revenue over a 5-10 year timeline. This would leverage existing R&D and manufacturing capabilities.
- Geographic Market Penetration: While IMRIS is described as a "global leader," specific details on its geographic reach are not provided. There is an opportunity to deepen market penetration in existing regions or expand into emerging markets where demand for advanced medical infrastructure is growing. Developing countries, in particular, are investing in healthcare upgrades, presenting a long-term growth avenue for sophisticated medical equipment. Strategic partnerships or direct sales force expansion in underserved regions could unlock new revenue streams, potentially over a 3-7 year horizon, capitalizing on increasing healthcare expenditure worldwide.
- Enhanced Service and Maintenance Offerings: Beyond initial system sales, IMRIS Inc. already offers comprehensive service plans and extended maintenance agreements. There is an opportunity to further enhance these offerings, potentially introducing tiered service packages, predictive maintenance solutions utilizing IoT, or specialized training programs for medical staff. These recurring revenue streams are often high-margin and can significantly improve customer loyalty and lifetime value. A robust service ecosystem ensures optimal system uptime and performance, which is critical for hospitals, and can provide stable revenue growth over the short to medium term (1-5 years).
- Technological Upgrades and Modality Integration: The medical imaging and surgical technology landscape is constantly evolving. IMRIS has an opportunity to continuously upgrade its VISIUS Surgical Theatre with newer imaging technologies, faster processing capabilities, or integration with emerging surgical robotics and artificial intelligence platforms. Incorporating advanced software features for image fusion, segmentation, or navigation could enhance the system's utility and appeal. These continuous innovations ensure the product remains at the forefront of surgical technology, attracting new customers and encouraging upgrades among existing ones, driving growth over a 2-6 year product cycle.
- Addressing Demand for Precision Medicine: The global trend towards precision medicine and personalized patient care underscores the importance of real-time, accurate intraoperative data. IMRIS's systems directly support this trend by providing immediate visual feedback crucial for complex procedures. As healthcare systems increasingly prioritize outcomes-based care and minimize patient morbidity, the demand for technologies that enhance surgical precision will likely continue to grow. IMRIS can capitalize on this macro trend by emphasizing the clinical benefits and economic value proposition of its systems, positioning itself as a key enabler of advanced surgical care over the next decade.
What Threats Does IMRSQ Face?
- Intense competition from larger, more diversified medical technology companies.
- Stringent and evolving regulatory approval processes for medical devices.
- Risk of technological obsolescence if innovation does not keep pace with industry advancements.
- Ongoing financial viability challenges and potential for further operational losses.
What Are IMRSQ's Competitive Advantages?
- Integrated System Design: The VISIUS Surgical Theatre offers a unique integration of multiple imaging modalities directly within the operating room, providing real-time data without patient transport.
- Specialized Niche Focus: Caters to high-acuity neurosurgical, spinal, and cardiovascular procedures, where precision and real-time feedback are paramount and competition for fully integrated solutions may be less fragmented.
- Proprietary Technology: Development and production of advanced image-guided therapy solutions likely involve proprietary hardware and software, creating barriers to entry for competitors.
- Clinical Efficacy and Precision: The system's ability to significantly boost treatment precision and aid critical decision-making provides a strong clinical value proposition for medical institutions.
What Does IMRSQ Do?
Based in Winnipeg, Canada, IMRIS Inc. was established in 2005 with a mission to revolutionize surgical procedures through advanced imaging technology. The company has since evolved into a global leader in the development, production, and distribution of sophisticated image-guided therapy solutions. At the core of its offering is the VISIUS Surgical Theatre, a highly advanced operating room environment designed to provide medical professionals with real-time, intraoperative visual data. This unique integration significantly enhances decision-making capabilities and boosts the precision of patient treatments across complex surgical interventions. The VISIUS Surgical Theatre is distinguished by its ability to seamlessly incorporate state-of-the-art imaging modalities, including magnetic resonance imaging (MRI), computed tomography (CT), and fluoroscopy, directly within multi-purpose surgical suites. This innovative approach brings diagnostic-quality imaging capabilities directly into the sterile operating field, eliminating the need to transport critically ill patients to separate imaging departments during procedures. This integration is crucial for a diverse range of medical procedures, particularly those in neurosurgical, spinal, cerebrovascular, and cardiovascular specialties, where real-time anatomical feedback can be life-saving. IMRIS Inc. primarily targets hospitals and medical centers that deliver high-acuity clinical care, providing them with comprehensive, integrated surgical environments. Beyond the initial installation of its core VISIUS systems, the company maintains ongoing relationships with its clients by offering a suite of complementary services. These include comprehensive service plans, extended maintenance agreements, and a variety of essential accessories and disposables, ensuring the long-term operational efficiency and clinical utility of its advanced surgical theatres. This business model supports both initial capital equipment sales and recurring revenue streams, solidifying IMRIS's position in the specialized medical device market.
What Products and Services Does IMRSQ Offer?
- Develops, produces, and distributes advanced image-guided therapy solutions.
- Offers the VISIUS Surgical Theatre, an integrated operating room environment.
- Provides real-time, intraoperative visual data to medical professionals during surgery.
- Integrates MRI, CT, and fluoroscopy directly into surgical suites.
- Aids critical decision-making and boosts precision in patient treatments.
- Serves neurosurgical, spinal, cerebrovascular, and cardiovascular specialties.
- Sells integrated theatres to hospitals providing clinical care.
- Provides comprehensive service plans, maintenance agreements, and accessories.
How Does IMRSQ Make Money?
- Capital Equipment Sales: Generates revenue from the sale and installation of its flagship VISIUS Surgical Theatre systems to hospitals and medical centers.
- Recurring Service Revenue: Earns ongoing income through comprehensive service plans and extended maintenance agreements for its installed base of systems.
- Accessory and Consumable Sales: Sells essential accessories and disposable components required for the operation and maintenance of its image-guided therapy solutions.
What Industry Does IMRSQ Operate In?
IMRIS Inc. operates within the highly specialized and technologically advanced medical device sector, specifically focusing on image-guided therapy solutions. This industry segment is characterized by continuous innovation, stringent regulatory requirements, and a strong emphasis on improving patient outcomes and surgical precision. The broader market for medical imaging and surgical navigation systems is driven by an aging global population, increasing prevalence of chronic diseases, and advancements in minimally invasive surgical techniques. IMRIS positions itself by integrating high-fidelity imaging modalities directly into the operating room, differentiating its VISIUS Surgical Theatre from traditional standalone imaging units. While the market for surgical equipment is competitive, IMRIS targets a niche requiring real-time intraoperative imaging for complex procedures like neurosurgery and cardiovascular interventions. This focus places it within a segment valuing advanced technology and integrated solutions, though it also faces competition from larger, more diversified medical technology companies.
Who Are IMRSQ's Key Customers?
- Hospitals and medical centers that provide high-acuity clinical care.
- Neurosurgical departments requiring real-time imaging during brain and spine procedures.
- Spinal surgery units benefiting from intraoperative guidance.
- Cerebrovascular specialists performing delicate procedures with imaging support.
- Cardiovascular surgery teams utilizing advanced imaging for heart and vessel operations.
Company Profile
IMRIS Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Minnetonka, US. The company is led by CEO Marc Buntaine. IMRSQ has traded publicly since 2023.
How IMRIS Inc. Is Valued
Relative to its peer group, IMRSQ's quantitative score of 46/100 is roughly in line with the peer average of 44/100.
Key Financial Metrics
Return on assets is -46.4%, showing how much profit it generates from its asset base. A current ratio of 1.10 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
IMRIS Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.51 places it in the distress zone, a signal of elevated financial risk.
IMRSQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- IMRSQ insiders seem to be holding steady, no major sell-offs recently which could signal confidence in the company's direction.
- The community is buzzing about potential new partnerships, even though details are scarce, the optimism is palpable.
- Market perception seems to be shifting, with more analysts mentioning IMRSQ in positive contexts lately.
- There's a general feeling that IMRSQ is undervalued, reminiscent of the early days of smaller tech companies before their breakout.
Bear Case
- The community is also raising concerns about increased competition in IMRSQ's sector, a valid threat to market share.
- Recent market developments suggest investors are becoming more risk-averse, which could negatively impact growth stocks like IMRSQ.
- Rumors are circulating about potential regulatory hurdles, though unconfirmed, such uncertainty can spook investors.
- Some community members are drawing parallels to companies that promised much but ultimately underdelivered, creating a cautious sentiment.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
IMRSQ Latest News
No recent news available for IMRSQ.
IMRSQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IMRSQ.
Price Targets
Wall Street price target analysis for IMRSQ.
IMRSQ MoonshotScore
What does this score mean?
The MoonshotScore rates IMRSQ 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Shalabh Chandra
Chief Executive Officer
Shalabh Chandra serves as the Chief Executive Officer of IMRIS Inc., a role in which he oversees the company's global operations and strategic direction. While specific details regarding his educational background, prior executive roles, or extensive career history are not provided in the available source data, his leadership encompasses the management of IMRIS Inc.'s 121 employees. His tenure is focused on guiding the company's efforts in developing, producing, and distributing advanced image-guided therapy solutions within the competitive healthcare sector.
Track Record: Specific achievements, strategic decisions, or company milestones directly attributable to Shalabh Chandra's leadership are not detailed in the provided source materials. His track record at IMRIS Inc. would involve navigating the company's operations within the medical device industry, managing its employee base, and overseeing its core business of intraoperative imaging solutions.
IMRSQ OTC Market Information
IMRIS Inc. trades on the OTC Other tier, which represents the lowest and most speculative segment of the over-the-counter market. Unlike companies listed on major exchanges like NYSE or NASDAQ, which adhere to strict listing standards regarding financial health, corporate governance, and minimum share prices, companies on the OTC Other tier have minimal or no public disclosure requirements. This tier typically includes companies that are financially distressed, in bankruptcy, or have ceased operations, and may not provide current information to investors. It signifies a significantly higher risk profile compared to regulated exchanges.
- OTC Tier: OTC Other
- Heightened risk of financial distress or bankruptcy due to minimal disclosure and potential operational issues.
- Lack of regulatory oversight compared to major exchanges, leading to reduced investor protections.
- Extremely low trading volume and wide bid-ask spreads, resulting in poor liquidity and price volatility.
- Difficulty in obtaining reliable and timely financial information due to unknown disclosure status.
- Increased susceptibility to fraud and manipulation given the limited transparency and oversight.
- Verify the company's current operational status and any recent public announcements.
- Attempt to locate any available financial statements or disclosures, however limited.
- Research any legal or regulatory actions against the company or its management.
- Assess the actual trading volume and bid-ask spread to understand liquidity.
- Investigate the company's business model viability and competitive landscape.
- Confirm the legitimacy of management and board members, if information is available.
- Understand the specific reasons for its OTC Other listing and lack of disclosure.
- Established in 2005, indicating a relatively long operational history.
- Described as a "global leader" in its niche, suggesting a degree of market presence.
- Operates in a specialized, high-tech segment of the medical device industry.
- Has a known CEO, Shalabh Chandra, and a stated employee count of 121.
Common Questions About IMRSQ (Healthcare)
What does the AI Score mean for IMRSQ?
IMRSQ holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. IMRIS Inc. is a Canadian healthcare company specializing in advanced image-guided therapy solutions, primarily through its VISIUS Surgical Theatre. This system integrates real-time MRI, CT, …
What does IMRIS Inc. do?
IMRIS Inc., founded in 2005 and based in Winnipeg, Canada, specializes in advanced image-guided therapy solutions for the healthcare sector. The company's primary offering is the VISIUS Surgical Theatre, an integrated operating room environment that incorporates real-time magnetic resonance imaging (MRI), computed tomography (CT), and fluoroscopy directly into surgical suites.
What distinguishes IMRIS Inc.'s VISIUS Surgical Theatre in the medical device market?
The VISIUS Surgical Theatre distinguishes itself by integrating multiple advanced imaging modalities—MRI, CT, and fluoroscopy—directly into a multi-purpose surgical suite. This unique capability allows surgeons to obtain real-time, high-resolution visual data during an ongoing procedure without the need to transport the patient to a separate diagnostic imaging department.
What are the primary financial challenges facing IMRIS Inc.?
IMRIS Inc. faces significant financial challenges, as indicated by its reported financial metrics. The company currently holds a market capitalization of $0.00B, suggesting a very small or potentially distressed valuation. A substantial negative profit margin of -105.2% highlights that the company is incurring significant losses relative to its revenue, indicating operational inefficiencies or insufficient sales volume to cover costs.
What are the implications of IMRIS Inc. trading on the OTC Other tier?
Trading on the OTC Other tier carries several implications for IMRIS Inc. and its investors. This tier is associated with the highest risk within the over-the-counter market, often indicating companies that are financially distressed, in bankruptcy, or have minimal to no public disclosure.
What are the key factors to evaluate for IMRSQ?
IMRIS Inc. (IMRSQ) holds an AI score of 46/100 (low). operates in a specialized segment of the medical device market, focusing on intraoperative imaging solutions through its VISIUS Surgical Theatre. Not financial advice.
How frequently does IMRSQ data refresh on this page?
IMRSQ's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven IMRSQ's recent stock price performance?
IMRIS Inc. (IMRSQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized and integrated VISIUS Surgical Theatre offers real-time intraoperative imaging (MRI, CT, fluoroscopy). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IMRSQ overvalued or undervalued right now?
IMRIS Inc. (IMRSQ) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Detailed financial history and specific operational metrics beyond the provided summary are not available.
- No analyst coverage, price targets, or consensus information was provided, so the relevant FAQ was omitted.
- Specific regulatory approval track record and processes for IMRIS Inc. are not detailed in the source data.
- No FMP PEER TICKERS were provided for competitors.
- CEO background and track record details are limited to name and employee count.